Beta-lactoglobulin

Beta-Lactoglobulin: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Beta-lactoglobulin (also written β-lactoglobulin; abbreviated BLG or β-LG; allergen designation Bos d 5) is the major whey protein of cow and sheep's milk, occurring at approximately 3 g/L, and is also present in many other mammalian species. It is a lipocalin protein that can bind many hydrophobic molecules, suggesting a role in their transport.

Molecular Structure

β-LG accounts for approximately 10–15% of total milk proteins and 58% of whey protein, exists at the normal pH of bovine milk as a dimer with a molecular weight of 36 kDa, and is a single-chain polypeptide of 18 kDa comprising 162 amino acid residues. The monomeric native-state structure comprises an eight-stranded continuous antiparallel β-barrel and one major α-helix. Under physiological conditions it is predominantly dimeric, but dissociates to a monomer below about pH 3, preserving its native state; BLG also occurs in tetrameric, octameric, and other multimeric aggregation forms under a variety of natural conditions.

Genetic Variants

In cattle, twelve polymorphic variants of β-LG have been identified (A, B, C, D, E, F, G, W, H, I, J, and X). The two most common variants, A and B, have been specifically linked to variations in milk protein yield and composition. The β-LG A and B variants differ by two amino acid substitutions in the polypeptide chain arising from two single-nucleotide substitutions in the β-Lg-I gene: in the A variant, Aspartic acid 64 (GAT) is changed to Glycine (CGT), while Valine-118 (GTC) is changed to Alanine (GCC) in the B variant. All the variants contain five cysteine residues, four of which are involved in forming intra-chain disulphide bridges.

Amino Acid Profile

Beta-lactoglobulin is a globular protein of the lipocalin family with a molecular weight of 18,300 and comprises 162 amino acid residues, including a relatively high proportion of branched-chain amino acids (BCAAs); it contains 22 leucine, 10 isoleucine, and 9 valine residues (10 in the A variant), making it one of the richest known food proteins in these amino acids. The leucine content of BLG exceeds the constituent leucine content of whole whey protein by approximately 50% (~15% vs. ~10%).

Species Distribution

Beta-lactoglobulin is the major whey protein in milk of cows and other ruminants such as deer, bison and buffalo, and in some non-ruminants such as pigs, horses, dogs, dolphins and whales; however, it is not an endogenous part of human milk. It is highly abundant in whey, accounting for 50% of total protein in the lactoserum fraction and approximately 10% in cow's milk; it has no homologous counterpart in human milk.

Physical and Thermal Properties

The heat denaturation of β-LG occurs between 70 and 75°C and forms aggregates at 78 to 82°C. High protein content products such as whey protein isolate (WPI) are enriched with β-LG; the high content of β-LG in WPI leads to enhanced functional properties including emulsion stability, activity, viscosity, and gelling properties compared with whey protein concentrate (WPC).

2. Natural Sources and Common Preparations

Primary Source

The major protein in whey is β-lactoglobulin, followed by α-lactalbumin (β-lactoglobulin ≈ 65%, α-lactalbumin ≈ 25%, serum albumin ≈ 8%, other ≈ 2%). BLG is therefore encountered wherever dairy whey is found, including in cheese production byproducts, fluid whey, and commercial whey processing streams.

Isolation and Purification

To isolate β-LG, milk is first converted to skimmed milk by removing fat globules, then casein protein is removed by acidification to pH 4.6; β-LG is subsequently isolated by gel filtration chromatography (e.g., Sephacryl S-200) from the supernatant whey protein fraction, and can be further purified by anion-exchange chromatography.

Commercial Forms

BLG is commercially available as an isolated, highly purified single protein ingredient distinct from standard whey protein concentrate or whey protein isolate. Lacprodan® BLG-100 (manufactured by Arla Foods Ingredients) is a pure β-lactoglobulin derived from whey that delivers a unique amino acid profile and approximately 4% more leucine compared to whey protein. It is also encountered in food systems as an ingredient in dairy products, protein supplements, beverages, and sports nutrition formulations. Generation of bioactive peptides from BLG may be induced in several ways: by enzymatic hydrolysis or microbial fermentation, in vivo during digestion by digestive enzymes such as trypsin, by gut microbial enzymes, during food processing by ripening, or by in vitro hydrolysis using isolated enzymes. Fermented dairy products including yogurt, sour milk, and cheese include a variety of naturally produced bioactive peptides derived partly from BLG. An additional specialized preparation is the holo-BLG (holoBLG) lozenge, in which BLG is loaded with iron and co-formulated with micronutrients including vitamin A and zinc for immunological applications (discussed under Clinical Evidence below).

3. Traditional and Historical Use

Beta-lactoglobulin as an isolated, characterized entity has no documented pre-modern traditional use distinct from milk and whey consumption in general. The protein was not identified or named as a specific constituent until the early twentieth century. Since its first isolation, bovine beta-lactoglobulin has been an enigma: although it is abundant in the whey fraction of milk, its function is still not clear.

The broader context is that whey — the watery fraction of milk from which BLG derives — has been consumed across many cultures for centuries as a food and folk remedy. However, these historical uses applied to unfractionated whey rather than to isolated BLG, and cannot be attributed specifically to this protein. β-LG is of great importance to the dairy industry, similar to other whey proteins, and is particularly useful for controlling the texture of a variety of foods. Its specific identification, structural characterization, and study as a bioactive ingredient is an entirely modern scientific development.

There is therefore no documented traditional use specifically attributable to beta-lactoglobulin as a defined ingredient across any culture or time period; claims of traditional use in historical literature refer to whey as a whole and should not be extrapolated to BLG specifically.

4. Key Constituents, Active Compounds, and Mechanisms of Action

4.1 The Intact Protein as a Lipocalin and Transporter

Beta-LG is the major whey protein of ruminant species and is also present in the milks of many, but not all, other species; its amino acid sequence and three-dimensional structure show that it is a lipocalin, a widely diverse family, most of which bind small hydrophobic ligands and thus may act as specific transporters, as does serum retinol binding protein. The protein binds cholesterol, vitamin D2, long-chain fatty acids, retinoids, and steroids within its central binding cavity. This suggests a role for BLG in vitamin A transport, and specific receptors for the BLG-retinol complex have been discovered in the intestine of neonate calves. BLG has also been shown to be able to bind iron via siderophores and might have a role in combating pathogens.

4.2 Acid Resistance and Bioavailability

BLG's distinctive β-barrel structure contributes to enhanced bioavailability and sustained amino acid availability; its acid-resistant structure enables rapid gastric transit and intestinal hydrolysis during ingestion, forming bioactive peptides. This structural stability at low pH distinguishes BLG from many other food proteins and is relevant to its digestion kinetics.

4.3 Bioactive Peptides Derived from BLG

β-LG is currently an important source of biologically active peptides; these peptides are inactive within the sequence of the precursor protein, but they can be released by in vivo or in vitro enzymatic proteolysis; once released, these peptides play important roles in human health, including antihypertensive, antioxidant, and antimicrobial activities, as well as opioid-like features and the ability to decrease body cholesterol levels.

Key characterized bioactive peptides derived from BLG include:

• β-lactosin B (Ala-Leu-Pro-Met, residues f142–145): Various peptides derived from proteolytic digestion of β-LG have been shown to inhibit ACE (angiotensin-converting enzyme); intact β-LG has minimal ACE inhibitory activity, but peptides derived from digestion with pepsin, trypsin, or chymotrypsin have high activity. Perhaps the most promising ACE-inhibiting peptide is the tetrapeptide "β-lactosin B" (alanine-leucine-proline-methionine; derived from the f142–145 sequence), which has been shown to have antihypertensive activity.
• β-Lactolin (Gly-Thr-Trp-Tyr, GTWY): The β-lactopeptide of glycine-threonine-tryptophan-tyrosine (GTWY), β-lactolin, is derived from β-lactoglobulin in whey proteins digested by specific enzymes; WY-related peptides such as GTWY are abundant in fermented dairy products, including camembert cheese. Orally administered β-lactolin has been shown to be delivered to the brain, inhibit monoamine oxidase, and increase monoamine levels in the frontal cortex and hippocampus, resulting in improvements in spatial working memory and object recognition memory in mice.
• Lactostatin (IIAEK): The peptide IIAEK (lactostatin) derived from bovine milk β-lactoglobulin has shown strong cholesterol-lowering effects in in vivo animal studies, exhibiting a greater activity in comparison with that of the drug β-sitosterol.
• β-Lactotensin (His-Ile-Arg-Leu): The four-residue bioactive peptide β-lactotensin (β-LT; His-Ile-Arg-Leu) was isolated from BLG. Preclinical data suggest neurotensin receptor–mediated effects on stress responses, though human evidence is absent.

4.4 Anabolic Signaling

Leucine initiates muscle protein synthesis by activating the mammalian target of rapamycin (mTOR) and downstream targets. BLG's nutritional profile is rich in essential amino acids, branched chain in particular, including leucine, containing around 1.5 times more leucine than standard whey or casein protein; BLG activates the mTOR pathway and stimulates muscle protein synthesis even under inflammatory conditions.

4.5 Incretin and Glucoregulatory Mechanisms

Preclinical studies in mouse and cell models demonstrate glucose-lowering effects of BLG comparable to metformin, mediated by DPP-4 and α-glucosidase inhibition, AMPK activation, and stimulation of hepatic glucose uptake. The underlying mechanisms of whey protein's insulin-stimulating effects are only partly understood but may involve stimulation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and insulin secretion together with a slower gastric emptying rate.

4.6 Immunological Properties — the Holo vs. Apo Form

The apo-form (iron-free BLG) promotes Th2 cells and inflammation, whereas the holo-form (iron-loaded BLG) appears to be immunosuppressive. Atopic patients have micronutritional deficiencies in innate immune cells, especially ferric iron complexed with siderophores, vitamins, and zinc; these deficiencies drive regulatory cells into an inflammatory state and negatively affect Th1 cell survival, resulting in Th2 hypersensitivity; holoBLG has been developed as a "Trojan horse" to shuttle micronutrients into atopic immune cells, an approach that was preclinically and clinically effective to correct these intracellular deficiencies and thereby alleviate allergic symptoms.

5. Scientific Evidence by Area of Use

5.1 Muscle Protein Synthesis and Skeletal Muscle Health

Mechanistic and preclinical rationale: BLG is a protein found within whey protein that is rich in essential amino acids, most notably leucine; leucine is considered the most potent essential amino acid (EAA) in the postprandial stimulation of muscle protein synthesis (MPS), such that suboptimal protein/EAA doses containing higher leucine content can elicit muscle anabolism comparable to larger protein doses.

Human clinical study (MPS, crossover design, 2025): A study by Ely et al. tested the effects of naturally leucine-rich BLG (~10 g protein) versus isonitrogenous whey protein isolate (WPI, ~10 g) on MPS; ten healthy young men (26 ± 2 years) received BLG (1.57 g leucine) or WPI (1.02 g leucine) in a randomized double-blind crossover fashion; a primed constant intravenous infusion of [1,2-¹³C₂] leucine was used to determine MPS at baseline and in response to feeding and feeding-plus-exercise. Both BLG and WPI effectively stimulated MPS in young healthy males, with BLG offering an advantage in EAA/BCAA/leucine bioavailability.

Clinical study protocol (immobilization/prehabilitation): A parallel, double-blind, 2-arm, randomized placebo-controlled trial recruited 24 healthy young (18–45 years) males and females; the intervention group combined a 7-day structured resistance exercise training programme with thrice-daily dietary supplementation of 23 g of β-lactoglobulin; the placebo group combined the same training programme with an energy-matched carbohydrate (dextrose) control. This study was designed to evaluate whether pre-immobilization BLG supplementation could mitigate disuse-induced decline in MPS.

Human study (insulinotropic and catabolic conditions): Plasma concentrations of leucine at the end of the sipping period were significantly higher following BLG compared with both whey protein isolate and casein.

Evidence strength: Evidence for BLG's superiority over standard whey in MPS at matched protein doses is preliminary, based on a small single crossover study (n = 10). Larger, longer-duration trials comparing BLG directly to whey or casein across different populations and at various doses are needed before firm conclusions can be drawn.

5.2 Glycemic Regulation and Type 2 Diabetes

Clinical study (randomized double-blind crossover, T2DM): Sixteen participants with T2DM were investigated using a randomized double-blinded cross-over design with two pre-meal interventions — (i) 25 g BLG and (ii) 25 g WPI — prior to an oral glucose tolerance test (OGTT), followed by four days of continuous glucose monitoring (CGM) at home. BLG increased concentrations of insulin by 10%, glucagon by 20%, and glucose by 10% compared with WPI after the OGTT (all p < 0.05). Both BLG and WPI reduced interstitial fluid glucose concentrations (using CGM) by 2 mM and lowered glycemic variability by 10–15% compared with tap water (p < 0.05), and WPI lowered the ISF glucose by 0.5 mM compared with BLG from 120 min onward (p < 0.05). In conclusion, BLG pre-meals resulted in higher insulin, glucagon, and glucose concentrations compared with WPI in participants with T2DM; pre-meal servings of WPI remained the most potent protein in terms of lowering postprandial glucose excursions.

Study limitations: The T2DM crossover trial had only 16 participants and was supported by Arla Foods Ingredients (an industry funder). The study was supported by Arla Foods Ingredients Group P/S, and one author was employed as a nutrition research scientist at Arla Foods Ingredients Group P/S. The finding that BLG raised both insulin and postprandial glucose more than WPI suggests that BLG is not superior to WPI for glucose management in T2DM. Preclinical mechanistic data are more promising but cannot be directly extrapolated to humans.

Evidence strength: Preliminary; one small crossover trial shows BLG's insulinotropic properties are greater than WPI, but net glycemic benefit in T2DM appears inferior to standard whey protein isolate. More human trials are required.

5.3 Cognitive Function and Neuroprotection (β-Lactolin)

Background: Epidemiological studies have shown that dairy product consumption is beneficial for cognitive function in elderly individuals; β-lactolin is a Gly–Thr–Trp–Tyr lactotetrapeptide rich in fermented dairy products that improves memory retrieval, attention, and executive function in older adults with subjective cognitive decline and prevents the pathology of Alzheimer's disease in rodents.

Randomized, double-blind, placebo-controlled trial (12 weeks, n=114): 114 healthy subjects aged 50–75 were supplemented with a whey peptide (containing β-lactolin) or placebo for 12 weeks, and changes in cognitive function were assessed using neuropsychological tests at weeks 0, 6, and 12 of the intervention. In this trial, the daily supplement contained 1.6 mg of GTWY (β-lactolin).

Randomized controlled trial (cerebral blood flow, n=50): β-Lactolin effects on cerebral blood flow (CBF) were examined using near-infrared spectroscopy (NIRS) in a placebo-controlled randomized double-blind study; 50 healthy participants (aged 45–60 years) were randomly allocated into the β-lactolin or the placebo group (n = 25 each) and supplemented for 6 weeks. Changes in oxy-hemoglobin (representing CBF) located at the left dorsolateral prefrontal cortex (DLPFC) during the spatial working memory task showed higher statistical significance in the β-lactolin group.

Randomized controlled trial (EEG neural activity, n=30): A randomized, double-blind, placebo-controlled study investigated the effects of β-lactolin on neural activity using event-related potential (ERP) measurements obtained through EEG; 30 Japanese-speaking healthy adults, aged 45–64 years, who were self-aware of forgetfulness, were enrolled.

Integrated analysis of multiple RCTs: Previous clinical trials have demonstrated that supplementation with whey peptide rich in β-lactolin improves memory retrieval, attention, and executive function in the elderly and promotes neural activity in the cortex and cerebral blood flow.

Preclinical data: In aged mice, the number of activated microglia in the hippocampus and cortex and the production of cytokines (tumor necrosis factor-α, macrophage inflammatory protein-1α, and macrophage chemoattractant protein-1) were increased compared with young mice, but were reduced in aged mice fed β-lactolin; age-related hippocampal atrophy was also improved in aged mice fed β-lactolin.

Evidence strength: Multiple small-to-moderate-sized RCTs from primarily Japanese research groups have examined β-lactolin's effects on cognition, with consistent positive signals. However, sample sizes are modest (30–114 participants), study durations are short (6–12 weeks), most studies were conducted in Japanese populations only, and several were conducted or funded by Kirin Holdings Company, raising potential bias concerns. Evidence is promising but not yet sufficient to constitute clinical proof of efficacy.

5.4 Allergy and Immune Resilience (HoloBLG)

Biological rationale: Clinical studies have shown that holo beta-lactoglobulin (holoBLG) can restore micronutritional deficits in atopic immune cells and alleviate allergic symptoms in a completely allergen-nonspecific manner. The apo-form promotes Th2 cells and inflammation, whereas the holo-form appears to be immunosuppressive.

Open pilot study in cat allergy (n=35, allergen exposure chamber): Patients with clinically relevant cat allergy were provoked with cat allergen for 120 minutes in an allergen exposure chamber before and after a 3-month intervention phase (holoBLG lozenge twice daily). Nasal, conjunctival, bronchial, and pruritus symptoms were scored every 10 minutes, constituting a total symptom score (TSS); peak nasal inspiratory flow (PNIF) was measured every 30 minutes. Thirty-five patients (mean age: 40 years) completed the study; compared to baseline, holoBLG supplementation resulted in significant improvement in median TSS of 50% (p < 0.001), as well as in median nasal flow by 20 L/min (p = 0.0035). Cat allergic patients profited from targeted micronutrition with the holoBLG lozenge; as previously seen in other allergies, holoBLG supplementation also induced immune resilience in cat allergies, resulting in significant symptom amelioration.

Formulation: The holoBLG lozenge (immunoBON®, manufactured by Biomedical International R+D GmbH, Vienna, Austria) contains the whey protein beta-lactoglobulin combined with micronutrients: iron complexed with catechins from cocoa extract, vitamin A, and zinc. In adults, the lozenge is taken twice daily over a period of 3 months.

Evidence strength: Open-label pilot study without a placebo arm; results are promising and mechanistically grounded, but the absence of blinding and randomization limits causal inference. Larger, controlled trials are needed.

5.5 Antihypertensive Effects via Bioactive Peptides

Many of the bioactivities attributed to β-LG are derived from peptides produced by enzyme hydrolysis and largely studied in isolated cell systems; these bioactivities include inhibition of angiotensin-converting enzyme (ACE inhibitor) and antimicrobial activity; intact β-LG has minimal ACE inhibitory activity, but peptides derived from digestion with pepsin, trypsin, or chymotrypsin have high activity; most of these studies demonstrate ACE inhibition using in vivo or in vitro systems.

Evidence strength: Preclinical only; while BLG-derived ACE-inhibitory peptides (most notably β-lactosin B) show consistent activity in cell and animal systems, no published controlled human trials directly attributing antihypertensive effects to BLG-specific peptide supplementation could be identified from authoritative sources. This area remains at the preclinical stage.

5.6 Antimicrobial and Cholesterol-Modulating Peptides

Hydrolysis of whey proteins can generate bioactive peptides having antioxidant, antimicrobial, antihypertensive, and antidiabetic activities. The peptide IIAEK (lactostatin) derived from bovine milk β-lactoglobulin showed strong cholesterol-lowering effects in in vivo animal studies, exhibiting a greater activity in comparison with that of the drug β-sitosterol.

Evidence strength: Preclinical only; no human clinical trials specifically targeting BLG-derived antimicrobial or cholesterol-modulating peptides have been identified in peer-reviewed sources.

6. Body Systems and Health Areas

• Musculoskeletal system: Stimulation of muscle protein synthesis via leucine-mTOR pathway; of particular interest in aging, disuse atrophy, and exercise recovery.
• Metabolic / endocrine system: Insulinotropic and glucagonotropic effects; pre-meal protein strategy for postprandial glucose management; incretin pathway modulation (GLP-1, GIP).
• Central nervous system / cognition: Via the BLG-derived tetrapeptide β-lactolin: monoamine oxidase inhibition, increased dopaminergic tone in the prefrontal cortex and hippocampus, increased cerebral blood flow in DLPFC, improvement in working memory and attention in older adults.
• Immune system / allergy: Distinction between apo-BLG (pro-Th2/allergenic) and holo-BLG (immunomodulatory/tolerogenic); holoBLG as a delivery vehicle for micronutrients to atopic immune cells; allergen-nonspecific symptom reduction.
• Cardiovascular system: ACE-inhibitory peptides derived from enzymatic hydrolysis may contribute to blood pressure regulation (preclinical).
• Gastrointestinal / nutritional: Ligand transport of fat-soluble vitamins (retinol, vitamin D), fatty acids, and steroids in the intestinal lumen; cholesterol modulation via lactostatin (preclinical).

7. Dosage Forms and Doses Reported in Studies

• Isolated BLG protein powder (pre-meal, glucose/insulin studies): 25 g of BLG administered as a pre-meal bolus before an oral glucose tolerance test, in a randomized crossover trial in 16 participants with T2DM.
• Isolated BLG protein (MPS study): ~10 g of BLG protein (providing 1.57 g leucine) was administered in a randomized double-blind crossover study in healthy young men.
• Isolated BLG powder (prehabilitation/immobilization trial protocol): 23 g of β-lactoglobulin three times daily was used in the intervention arm of a parallel randomized placebo-controlled trial.
• Whey peptide containing β-lactolin (cognitive function trial): 1.6 mg of GTWY (β-lactolin) per daily supplement dose was used in a 12-week randomized, double-blind, placebo-controlled study in 114 healthy older adults aged 50–75.
• HoloBLG lozenge (allergy, immune resilience): HoloBLG lozenge administered twice daily for 3 months in a pilot study of cat-allergic patients.

8. Safety Considerations and Interactions

8.1 Cow's Milk Protein Allergy (CMPA)

β-LG is a major allergenic milk protein (Bos d 5), accounting for approximately 50% of whey protein and 10% of the total protein content of milk. Sensitization to Bos d 5 occurs in 80% of patients with CMPA, and cross-reactivity of the protein with other food allergens is possible. Cow milk allergy represents one of the most common food allergies, affecting between 1.8% to 7.5% of infants during the first year of life; in the majority of cases (85–90%), milk allergy resolves, but children who have outgrown milk allergy still have a higher risk of developing atopic eczema, egg allergy, or allergic asthma.

8.2 Absence from Human Milk

Beta-lactoglobulin is considered a milk allergen; it is not an endogenous substance in human, rodent, or lagomorph milk. This evolutionary absence from human milk is considered relevant to its allergenic potential in infants.

8.3 IgE Epitopes and Persistent Allergy

The molecule contains several IgE epitopes, which are located (exposed) on its surface; patients with IgE-mediated cow's milk allergy have been shown to have seven IgE and six IgG binding epitopes, while in younger patients only three of these IgE binding epitopes are recognized; a large number of β-lactoglobulin epitopes may be a marker of persistent cow's milk allergy.

8.4 Thermal Processing and Antigenicity

The heat denaturation of β-LG occurs between 70 and 75°C and it forms aggregates at 78 to 82°C. Heat treatment reduces but does not eliminate the allergenicity of BLG; high-heat processing (such as autoclaving or UHT treatment) can substantially reduce IgE-binding capacity, but this varies by processing conditions and individual sensitivity.

8.5 Unexpected Exposure Routes

Beta-lactoglobulin has been detected in house dust and cosmetics, presenting potential non-dietary exposure routes for sensitized individuals.

8.6 Cross-Reactivity

Antibodies to beta-lactoglobulin show approximately 10% cross-reactivity with bovine α-lactalbumin.

8.7 Drug and Nutrient Interactions

Beta-lactoglobulin can be used as a transporter for drugs in cancer treatment because of the physicochemical properties of the protein and its ability to bind a wide range of different ligands. This binding capacity — encompassing hydrophobic vitamins, fatty acids, and steroids — theoretically has the potential to influence the bioavailability of co-administered lipophilic compounds, though this has not been studied in controlled clinical trials. In the T2DM glucose management study, participants taking anti-glycemic medication other than metformin were excluded, along with those with milk allergies and daily users of protein supplements.

8.8 Phosphorus Content and Renal Disease

BLG is naturally low in phosphorus relative to casein, which has been noted as potentially advantageous in clinical nutrition contexts where phosphorus restriction is indicated, though controlled clinical evidence in renal patients is lacking.

References

• Sawyer L. Invited review: beta-lactoglobulin: binding properties, structure, and function. Journal of Dairy Science, 2004.
• Papiz MZ et al. The structure of beta-lactoglobulin and its similarity to plasma retinol-binding protein. Nature, 1986.
• Beta-Lactoglobulin — ScienceDirect Topics Overview.
• β-Lactoglobulin — Wikipedia (citing primary peer-reviewed sources).
• Mukhopadhyay S et al. Isolation and purification of beta-lactoglobulin from cow milk. Veterinary World, 2016. PMC4774723.
• Jann OL et al. Genotyping of β-Lactoglobulin gene by PCR-RFLP in Sahiwal and Tharparkar cattle breeds. Pakistan Journal of Biological Sciences, 2004. PMC1538624.
• Boushaba N et al. Allele and genotype frequencies of β-lactoglobulin gene using PCR-RFLP in Algerian local cattle populations. PMC10644313.
• Ely IA et al. β-Lactoglobulin: A novel bioactive whey protein with incretin-modulating and muscle anabolic properties. Journal of Nutritional Physiology, 2025.
• Mose M et al. β-Lactoglobulin Elevates Insulin and Glucagon Concentrations Compared with Whey Protein — A Randomized Double-Blinded Crossover Trial in Patients with Type Two Diabetes Mellitus. Nutrients, 2021. PMC7911205.
• Ely IA et al. The Effect of Leucine-Enriched β-Lactoglobulin Versus an Isonitrogenous Whey Protein Isolate on Skeletal Muscle Protein Anabolism in Young Healthy Males. Nutrients, 2025. PMC12611059.
• Rogers LM et al. The effect of combined β-lactoglobulin supplementation and resistance exercise training prior to limb immobilisation on muscle protein synthesis rates in healthy young adults: study protocol for a randomised controlled trial. Trials, 2023. PMC10265785.
• Kita M et al. Supplementation With Whey Peptide Rich in β-Lactolin Improves Cognitive Performance in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study. Frontiers in Neuroscience, 2019. PMC6491855.
• Ano Y et al. β-Lactolin Reduces Age-Related Inflammation and Cognitive Decline. Frontiers in Aging Neuroscience, 2021. PMC8419277.
• Ano Y et al. β-lactolin increases cerebral blood flow in dorsolateral prefrontal cortex in healthy adults: a randomized controlled trial. Aging, 2020. PMC7585116.
• Kanatome A et al. β-Lactolin Enhances Neural Activity, Indicated by Event-Related P300 Amplitude, in Healthy Adults: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021. PMC8203246.
• Fukuda T et al. Effect of Whey-Derived Lactopeptide β-Lactolin on Memory in Healthy Adults: An Integrated Analysis of Data from Randomized Controlled Trials. Journal of Nutrition, Health & Aging, 2022. PMID 35166303.
• Bergmann KC et al. The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy — Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge. Clinical and Translational Allergy, 2023. PMC10314279.
• Roth-Walter F et al. The Major Cow Milk Allergen Bos d 5 Manipulates T-Helper Cells Depending on Its Load with Siderophore-Bound Iron. PLoS ONE, 2014. PMC4130594.
• Mori F et al. Usefulness of nBos d 4, 5 and nBos d 8 Specific IgE Antibodies in Cow's Milk Allergic Children. Allergy, Asthma & Clinical Immunology, 2014. PMC3936039.
• Benedé S et al. Cow's Milk Processing — Friend or Foe in Food Allergy? Nutrients, 2021. PMC8000412.
• Wierzbicka M et al. Enhanced Effect of β-Lactoglobulin Immunization in Mice with Mild Intestinal Deterioration. Nutrients, 2024. PMC11510979.
• Hernández-Ledesma B et al. β-Lactoglobulin as source of bioactive peptides. Amino Acids, 2008.
• Marcone S et al. Dairy bioactive proteins and peptides: a narrative review. Nutrition Research Reviews, 2022. PMC8653944.
• Lordan R et al. Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis. Journal of Functional Foods, 2017. PMC5338169.
• Fahmy HA et al. Milk-Derived Antimicrobial Peptides: Overview, Applications, and Future Perspectives. Pharmaceutics, 2022. PMC9649404.
• Nicolai T et al. Beta-Lactoglobulin as a Model Food Protein: How to Promote, Prevent, and Exploit Its Unfolding Processes. Molecules, 2022. DOI: 10.3390/molecules27031131.
• Mose M et al. β-Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. Journal of Nutrition, 2022.